Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbapenem versus piperacillin/tazobactam for febrile neutropenia in hospitalized adult cancer patients
IRCT20100127003210N27Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jul 2023
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of piperacillin + tazobactam in febrile neutropenia (FN) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Confirmed infection, Fever detection and 2 more. Started Jul 2023; status: completed.
02
Drugs
piperacillin + tazobactam
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on IRCT20100127003210N27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100127003210N27.